Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyskinesias
Parkinson Disease
Movement Disorders
Parkinsonian Disorders
Anti-Dyskinesia Agents

Interventions

DRUG: AFQ056
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals